Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2017 | Venetoclax combination therapy for relapsed CLL

Anna Schuh • 9 Dec 2017
ASH 2017
Chronic Lymphocytic Leukemia Ibrutinib Obinutuzumab Venetoclax
CLARITY

While single agents are able to control relapsed chronic lymphocytic leukemia (CLL) well, they do not provide a cure. In this interview, Anna Schuh, MD, PhD, from the University of Oxford, Oxford, UK, discusses recent data regarding the use of combination therapy for the treatment of relapsed CLL, such as venetoclax with ibrutinib or antibody therapy. Prof. Schuh highlights the promising results of the CLARITY study (ISRCTN13751862) of ibrutinib in combination with venetoclax, which produced impressive MRD negativity rates. This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.

More from Anna Schuh

AI-REAL: improving diagnosis and treatment in EBV-associated Burkitt lymphoma
Anna Schuh • 25 Mar 2024
3:04
Facilitating diagnosis of Burkitt lymphoma in children in Uganda and Tanzania
Anna Schuh • 7 Oct 2023
1:48
The OxPLoreD study: T-cell type abundance and gene expression in early lymphoproliferative disorders
Anna Schuh • 7 Oct 2023
1:52
Genomic stratification of patients with CLL
Anna Schuh • 7 Oct 2023

Related Videos

3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
3:18
A Phase I study of JBH492, an anti-CCR7 antibody-drug conjugate, in lymphoid malignancies
Pau Abrisqueta • 5 Apr 2024
0:44
Early detection and interception across hematological cancers
Irene Ghobrial • 8 Apr 2024
1:21
Monoclonal B-cell lymphocytosis: a disease to be (or not to be)
Paolo Ghia • 7 Apr 2024
The content of VJHemOnc is intended for healthcare professionals